Trial Profile
A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10296 in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Aumolertinib (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms APOLLO
- Sponsors Jiangsu Hansoh Pharmaceutical
- 27 Dec 2022 Planned End Date changed from 1 Nov 2022 to 31 Mar 2023.
- 18 Nov 2021 Primary endpoint has (Overall Response Rate (ORR) Phase II Part) been met according to the results published in the Journal of Thoracic Oncology
- 18 Nov 2021 Results (n=244; data cutoff: May 1, 2020) published in the Journal of Thoracic Oncology